Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 8/20 | 0.58 |
| ▸ | SYK | P43405 | 6/20 | 0.53 |
| ▸ | AURKA | O14965 | 2/20 | 0.51 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.50 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.50 |
| ▸ | CDK2 | P24941 | 1/20 | 0.50 |
| ▸ | CDK9 | P50750 | 1/20 | 0.50 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.47 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.47 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2061066 | 0.88 | ALK (0.55) | SCN9AJAK1TYK2CSNK2A2CSNK2B | |
| SCHEMBL267189 | 0.87 | EGFR (0.50) | SCN9ASYKCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL12519774 | 0.86 | MAPK1 (0.54) | SYKAURKA | |
| SCHEMBL23754828 | 0.86 | ALK (0.48) | SCN9ASYKJAK1TYK2CSNK2A2 | |
| SCHEMBL30086205 | 0.86 | ALK (0.48) | SCN9ASYKJAK1TYK2CSNK2A2 | |
| SCHEMBL656857 | 0.85 | SYK (0.60) | SYKAURKACCNT1CCNE1CDK2 | |
| SCHEMBL13794335 | 0.84 | CSNK2A1 (0.48) | SCN9AJAK1TYK2CSNK2A2CSNK2B | |
| SCHEMBL27612367 | 0.83 | SCN9A (0.50) | SCN9ASYK | |
| SCHEMBL2300114 | 0.83 | SYK (0.50) | SCN9ASYKCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL13788890 | 0.82 | PIN1 (0.63) | SCN9AAURKACSNK2A2CSNK2BCSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9334269-B2 | Carboxamides as inhibitors of voltage-gated sodium channels | AMGEN INC. (US) | 2016-05-10 | — | — | US | disclosed |
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | AMGEN INC. (US) | 2013-05-23 | — | — | US | disclosed |
| EP-2536689-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | Amgen Inc. (US) | 2012-12-26 | — | — | EP | disclosed |
| WO-2011103196-A1 | ARYL CARBOXAMIDE DERIVATIVES AS SODIUM CHANNEL INHIBITORS FOR TREATMENT OF PAIN | AMGEN INC. (US) | 2011-08-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131035-A1 | CARBOXAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS | CACNA1B, SCN1A, CACNA1I | SCN9A 18/4885SYK 3462/4885AURKA 2817/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.